Tamoxifen-based Treatment Induces Clinically Meaningful Responses in Multiple Myeloma Patients with Relapsing Disease after Autotransplantation

References

• Attal M., Harousseau J. L., Stoppa A. M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Barlogie B., Jagannath S., Vesole D. H., et al. Superiority of tandem autologous transplantation over standard therapy for untreated multiple myeloma. Blood 1997; 89: 789–793
   PubMed Web of Science ®Google Scholar
• Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Treono S. P., Teoh G., Urashima M., et al. Antiestrogens induce apoptosis of multiple myeloma cells. Blood 1998; 92: 1749–1757
   PubMed Web of Science ®Google Scholar
• Otsuki T., Yamada O., Kurebayashi J., et al. Estrogen receptors in human myeloma cells. Cancer Res. 2000; 60: 1434–1441
   PubMed Web of Science ®Google Scholar
• Guvakova M. A., Surmacz E. 'Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res. 1997; 57: 2606–2610
   PubMed Web of Science ®Google Scholar
• Kanter-Lewensohn L., Gimita L., Girnita A., et al. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-I (IGF-I) pathway. Mol Cell Endocrinol. 2000; 165: 131–137
   PubMed Web of Science ®Google Scholar
• Barrera P., Haagsma C. J., Boerbooms A. M., et al. Effect of methotrexate alone in or combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists: longitudinal evaluation in patients with rheumatoid arthritis. Br. J. Rheumatol. 1995; 34: 747–755
   PubMedGoogle Scholar
• Vacca A., Ribatti D., Roncali L., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 1994; 87: 503–508
   PubMed Web of Science ®Google Scholar
• Tricot G., Sawyer J. R., Jagganath S., et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J. Clin. Oncol. 1997; 15: 2659–2666
   PubMed Web of Science ®Google Scholar
• Osborne C. K. Drug therapy: tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 1998; 339: 1609–1618
   PubMed Web of Science ®Google Scholar
• Trump D. L., Smith D. C., Ellis P. G., et al. Highdose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J. Nail. Cancer 1992; 84: 1811–1816
   PubMed Web of Science ®Google Scholar
• Narasimhan P. Tamoxifen in the treatment of refractory lymphoma. N. Engl. J. Med. 1984; 11: 1258–1259
   Google Scholar
• Barrier J. H., Noan H. L., Mussini J. M., Brisseau J. M. Stabilisation of a severe case of P.O.E.M.S. syndrome after tamoxifen administration. J. Neurol. Neurosurg. Psychiatry 1989; 52: 286–290
   PubMed Web of Science ®Google Scholar
• Georgii-Hemming P., Wikiund H. J., Ljunggren O., Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996; 88: 2250–2258
   PubMed Web of Science ®Google Scholar
• Ferlin M., Noraz N., Hertogh C., et al. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6 independent transduction pathway. Br. J. Haematol. 2000; 111: 626–634
   PubMed Web of Science ®Google Scholar
• Xu F., Gardner A., Tu Y., et al. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br. J. Haematol. 1997; 97: 429–440
   PubMed Web of Science ®Google Scholar
• Ge N.-L., Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 286–2861
   Google Scholar
• Rajkumar S. V., Leong T., Roche P. C., et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin. Cancer Res. 2000; 6: 3111–3116
   PubMed Web of Science ®Google Scholar
• Gagliardi A. R., Hennig B., Collins D. C. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res. 1996; 16: 1101–1106
   PubMed Web of Science ®Google Scholar
• Hyder S. M., Nawaz Z., Chiappetta C., Stancel G. M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res. 2000; 60: 183–190
   Google Scholar
• Dankbar B., Padró T., Leo R., et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 26350–26360
   Google Scholar
• Gahrton G. 'Treatment of multiple myeloma. Lancet 1999; 353: 85–86
   PubMed Web of Science ®Google Scholar